ABLYNX Strengthens Management Team with the Appointment of Dr Debbie Law as Chief Scientific Officer - Gilde Healthcare

ABLYNX Strengthens Management Team with the Appointment of Dr Debbie Law as Chief Scientific Officer

January 8, 2009

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer.

Dr Law has over thirteen years experience in the biotech industry, with significant expertise in drug discovery and the successful progression of lead candidates into preclinical development. She will head up the research activities and identify and prioritise new therapeutic programmes that Ablynx will take forward to continue building its rapidly growing portfolio of Nanobody® development candidates.

Prior to joining Ablynx, Dr Law was at PDL BioPharma for five years where since 2006 she held the position of Vice President of Research. Previously she has also held senior research positions with EOS Biotechnology and COR Therapeutics.

Dr Law received her D. Phil. in immunology from the University Oxford in 1989 and followed this taking a post-doctoral position at the University of California, San Francisco.

Dr Edwin Moses, CEO and Chairman said: “We are delighted that Debbie is joining to head up the research activities at Ablynx. She brings with her a wealth of knowledge and experience in the drug discovery area with particularly strong expertise in biologics, which will further strengthen and complement our existing management team. We continue to rapidly advance our lead candidates towards the clinic and currently have two of our own Nanobodies® in clinical trials.”

Commenting on her appointment, Dr Law said: “I am joining Ablynx at a tremendously exciting time and I am looking forward to contribute to the creation of a very strong Nanobody® portfolio of products. I am impressed by the broad applicability of the Nanobody® technology to different target classes and therapeutic areas. I am also excited by the possibility of advancing alternative routes of delivery of Nanobodies®.”

-ends-

For more information, please contact:

College Hill Life Sciences for UK/International media enquiries:
Sue Charles, Justine Lamond,
Dr John McIntyre
t:   +44 (0)20 7866 7857
e:  ablynx@collegehill.com

Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / 
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / 
     +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com

Complete version of the press release in English [PDF]

Visit our website: www.ablynx.com

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
July 5, 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024